MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells. 2014

Kazuhiro Kitamura, and Masahiro Seike, and Tetsuya Okano, and Kuniko Matsuda, and Akihiko Miyanaga, and Hideaki Mizutani, and Rintaro Noro, and Yuji Minegishi, and Kaoru Kubota, and Akihiko Gemma
Corresponding Author: Masahiro Seike, Nippon Medical School, 1-1-5, Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan. mseike@nms.ac.jp.

Epithelial-mesenchymal transition (EMT) has recently been recognized as a key element of cell invasion, migration, metastasis, and drug resistance in several types of cancer, including non-small cell lung cancer (NSCLC). Our aim was to clarify microRNA (miRNA)-related mechanisms underlying EMT followed by acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in NSCLC. miRNA expression profiles were examined before and after transforming growth factor β1 (TGF-β1) exposure in four human adenocarcinoma cell lines with or without EMT. Correlation between expressions of EMT-related miRNAs and resistance to EGFR-TKI gefitinib was evaluated. miRNA array and real-time quantitative reverse transcription PCR (qRT-PCR) revealed that TGF-β1 significantly induced overexpression of miR-134, miR-487b, and miR-655, which belong to the same cluster located on chromosome 14q32, in lung adenocarcinoma cells with EMT. MAGI2 (membrane-associated guanylate kinase, WW, and PDZ domain-containing protein 2), a predicted target of these miRNAs and a scaffold protein required for PTEN, was diminished in A549 cells with EMT after the TGF-β1 stimulation. Overexpression of miR-134 and miR-487b promoted the EMT phenomenon and affected the drug resistance to gefitinib, whereas knockdown of these miRNAs inhibited the EMT process and reversed TGF-β1-induced resistance to gefitinib. Our study demonstrated that the miR-134/487b/655 cluster contributed to the TGF-β1-induced EMT phenomenon and affected the resistance to gefitinib by directly targeting MAGI2, in which suppression subsequently caused loss of PTEN stability in lung cancer cells. The miR-134/miR-487b/miR-655 cluster may be a new therapeutic target in patients with advanced lung adenocarcinoma, depending on the EMT phenomenon.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008565 Membrane Proteins Proteins which are found in membranes including cellular and intracellular membranes. They consist of two types, peripheral and integral proteins. They include most membrane-associated enzymes, antigenic proteins, transport proteins, and drug, hormone, and lectin receptors. Cell Membrane Protein,Cell Membrane Proteins,Cell Surface Protein,Cell Surface Proteins,Integral Membrane Proteins,Membrane-Associated Protein,Surface Protein,Surface Proteins,Integral Membrane Protein,Membrane Protein,Membrane-Associated Proteins,Membrane Associated Protein,Membrane Associated Proteins,Membrane Protein, Cell,Membrane Protein, Integral,Membrane Proteins, Integral,Protein, Cell Membrane,Protein, Cell Surface,Protein, Integral Membrane,Protein, Membrane,Protein, Membrane-Associated,Protein, Surface,Proteins, Cell Membrane,Proteins, Cell Surface,Proteins, Integral Membrane,Proteins, Membrane,Proteins, Membrane-Associated,Proteins, Surface,Surface Protein, Cell
D011799 Quinazolines A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring. Quinazoline
D002289 Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. Carcinoma, Non-Small Cell Lung,Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,Nonsmall Cell Lung Cancer,Carcinoma, Non Small Cell Lung,Carcinomas, Non-Small-Cell Lung,Lung Carcinoma, Non-Small-Cell,Lung Carcinomas, Non-Small-Cell,Non Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinomas
D002352 Carrier Proteins Proteins that bind or transport specific substances in the blood, within the cell, or across cell membranes. Binding Proteins,Carrier Protein,Transport Protein,Transport Proteins,Binding Protein,Protein, Carrier,Proteins, Carrier
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077156 Gefitinib A selective tyrosine kinase inhibitor for the EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) that is used for the treatment of locally advanced or metastatic NON-SMALL CELL LUNG CANCER. Iressa,N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide,ZD 1839,ZD1839
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D015153 Blotting, Western Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes. Immunoblotting, Western,Western Blotting,Western Immunoblotting,Blot, Western,Immunoblot, Western,Western Blot,Western Immunoblot,Blots, Western,Blottings, Western,Immunoblots, Western,Immunoblottings, Western,Western Blots,Western Blottings,Western Immunoblots,Western Immunoblottings
D015972 Gene Expression Regulation, Neoplastic Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue. Neoplastic Gene Expression Regulation,Regulation of Gene Expression, Neoplastic,Regulation, Gene Expression, Neoplastic

Related Publications

Kazuhiro Kitamura, and Masahiro Seike, and Tetsuya Okano, and Kuniko Matsuda, and Akihiko Miyanaga, and Hideaki Mizutani, and Rintaro Noro, and Yuji Minegishi, and Kaoru Kubota, and Akihiko Gemma
June 2018, Molecular medicine reports,
Kazuhiro Kitamura, and Masahiro Seike, and Tetsuya Okano, and Kuniko Matsuda, and Akihiko Miyanaga, and Hideaki Mizutani, and Rintaro Noro, and Yuji Minegishi, and Kaoru Kubota, and Akihiko Gemma
October 2015, International journal of oncology,
Kazuhiro Kitamura, and Masahiro Seike, and Tetsuya Okano, and Kuniko Matsuda, and Akihiko Miyanaga, and Hideaki Mizutani, and Rintaro Noro, and Yuji Minegishi, and Kaoru Kubota, and Akihiko Gemma
October 2014, Biochemical and biophysical research communications,
Kazuhiro Kitamura, and Masahiro Seike, and Tetsuya Okano, and Kuniko Matsuda, and Akihiko Miyanaga, and Hideaki Mizutani, and Rintaro Noro, and Yuji Minegishi, and Kaoru Kubota, and Akihiko Gemma
October 2012, FEBS letters,
Kazuhiro Kitamura, and Masahiro Seike, and Tetsuya Okano, and Kuniko Matsuda, and Akihiko Miyanaga, and Hideaki Mizutani, and Rintaro Noro, and Yuji Minegishi, and Kaoru Kubota, and Akihiko Gemma
June 2017, Scientific reports,
Kazuhiro Kitamura, and Masahiro Seike, and Tetsuya Okano, and Kuniko Matsuda, and Akihiko Miyanaga, and Hideaki Mizutani, and Rintaro Noro, and Yuji Minegishi, and Kaoru Kubota, and Akihiko Gemma
December 2017, Future oncology (London, England),
Kazuhiro Kitamura, and Masahiro Seike, and Tetsuya Okano, and Kuniko Matsuda, and Akihiko Miyanaga, and Hideaki Mizutani, and Rintaro Noro, and Yuji Minegishi, and Kaoru Kubota, and Akihiko Gemma
January 2018, Cancer cell international,
Kazuhiro Kitamura, and Masahiro Seike, and Tetsuya Okano, and Kuniko Matsuda, and Akihiko Miyanaga, and Hideaki Mizutani, and Rintaro Noro, and Yuji Minegishi, and Kaoru Kubota, and Akihiko Gemma
September 2016, Reproduction (Cambridge, England),
Kazuhiro Kitamura, and Masahiro Seike, and Tetsuya Okano, and Kuniko Matsuda, and Akihiko Miyanaga, and Hideaki Mizutani, and Rintaro Noro, and Yuji Minegishi, and Kaoru Kubota, and Akihiko Gemma
September 2013, The American journal of pathology,
Kazuhiro Kitamura, and Masahiro Seike, and Tetsuya Okano, and Kuniko Matsuda, and Akihiko Miyanaga, and Hideaki Mizutani, and Rintaro Noro, and Yuji Minegishi, and Kaoru Kubota, and Akihiko Gemma
October 2013, Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie,
Copied contents to your clipboard!